Botswana’s Cannabis Act 2025: Medicinal and Industrial Ambition in a Strictly Controlled Frame

Botswana has moved from near-total prohibition toward a regulated medicinal, scientific, research and industrial cannabis framework. The Cannabis Act 2025 established the legal basis. Subsequent amendments to the Illicit Traffic in Narcotic Drugs and Psychotropic Substances Act were passed to harmonise existing criminal law with the new licensed activities, explicitly allowing cultivation, production, storage, manufacture, import, export, transport, distribution and sale of medicinal cannabis and industrial hemp products under licence.

Recreational use remains illegal. The architecture is deliberately narrow: every stage from cultivation to distribution requires licensing, and the National Cannabis Control Authority has been stood up to oversee the system. Early implementation includes pilot activity and the identification of a public farm in Dibete for initial cultivation. Government messaging has framed the sector as a potential economic diversifier — “the new diamond” in some parliamentary contributions — capable of creating jobs and new value chains beyond minerals.

As of 2026 the framework is still in its early operational phase. Regulations governing licensing, security, tracking and quality are being bedded down. Investment interest, including international memoranda of understanding around industrial hemp, has appeared. Ordinary Batswana participation will depend on how accessible the licensing thresholds prove to be and whether downstream processing and domestic medical access develop beyond the initial pilot stage.

Enforcement against unlicensed possession and trafficking continues, as illustrated by periodic court cases involving multi-kilogram seizures. The policy choice is clear: open a controlled economic and medical channel while maintaining criminal sanctions for activity outside that channel.

Comparison with South Africa

Botswana’s approach is closer to the medical-and-industrial model seen in several Southern African jurisdictions than to South Africa’s constitutionally driven private-use starting point. South Africa has broader private adult rights but weaker commercial architecture. Botswana has clearer (if still new) commercial/medical legislation but no private adult-use rights. Both countries must still solve the inclusion problem: how smallholders, traditional knowledge holders and domestic patients fit into systems that currently favour capitalised, compliant operators.